COMPANY

Consano Bio, Inc.

HQ: Burlington, MA source · consanobio.com ↗

Keywords: musculoskeletal lumbosacral radiculopathy Lumbosacral Radicular Pain Sciatic Radiculopathy Sciatic Leg Pain Sciatica Lumbosacral Radicular Syndrome C-1101

Location: Burlington, MA · source · Oct 12, 2026

Profile checked Oct 10, 2026

$15.0MRaised (2 yrs)1Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $34.82M (Form D filed Mar 20, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001981285-26-000001 (Mar 20, 2026)
Evidence (2 events)
- Mar 20, 2026 · SEC Form D 0001981285-26-000001
  Name of Issuer: Consano Bio, Inc.; CIK: 1981285; Address: Burlington, MA; Submission type: D; Filing date: 2026-03-20; Industry Group: Biotechnology; Date of First Sale: 2026-03-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 48858795; Total Amount Sold: 34824466; Federal exemptions: 06b
- Dec 12, 2025 · SEC Form D 0001981285-25-000005
  Name of Issuer: Consano Bio, Inc.; CIK: 1981285; Address: Burlington, MA; Submission type: D; Filing date: 2025-12-12; Industry Group: Biotechnology; Date of First Sale: 2024-10-15; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 16840000; Total Amount Sold: 16840000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Undisclosed round · more than $15M · announced Oct 5, 2026 Company release ↗
Source quote
- Oct 5, 2026 · Company release ↗
  “Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Radiculopathy (Chronic Sciatica)”

Raises announced in these releases: $15M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Oct 5, 2026 Raise Private equity round: $15M (total, as published), announced Oct 5, 2026. Source: company's own press page. source ↗
Oct 5, 2026 Raise Undisclosed round · more than $15M source ↗
Dec 3, 2025 Trial start Phase 1: Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy source ↗

Upcoming milestones

Nov 1, 2026 (ESTIMATED) · Phase 1 · Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy · NCT07264270

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $15.0M. Last 2 years.

Oct 5, 2026 Private equity round: $15M (total, as published), announced Oct 5, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07264270	Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy	Phase 1	Recruiting	Dec 3, 2025	Nov 1, 2026 (estimated)